Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-209 plus carboplatin and gemcitabine versus carboplatin plus gemcitabine in advanced triple-negative breast cancer
CTR20261149Phase 3Active
- Sponsor
- BeBetter Med
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bebt-209 in triple-negative breast cancer (TNBC), sponsored by BeBetter Med. Started Jun 2026; status: active.
02
Drugs
bebt-209
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20261149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261149.